Esperion Therapeutics’ (ESPR) “Buy” Rating Reaffirmed at HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company’s stock.

ESPR has been the topic of several other reports. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Needham & Company LLC lowered their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th.

Esperion Therapeutics Trading Down 1.2 %

NASDAQ ESPR opened at $2.54 on Wednesday. The company has a 50-day moving average price of $2.09 and a two-hundred day moving average price of $2.16. Esperion Therapeutics has a 52 week low of $1.16 and a 52 week high of $3.40. The stock has a market cap of $500.48 million, a price-to-earnings ratio of -3.97 and a beta of 0.96.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Wasatch Advisors LP raised its stake in shares of Esperion Therapeutics by 38.4% in the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after buying an additional 6,483,070 shares in the last quarter. Vanguard Group Inc. grew its holdings in Esperion Therapeutics by 71.8% during the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after acquiring an additional 3,688,796 shares during the period. Geode Capital Management LLC raised its position in Esperion Therapeutics by 4.1% in the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after acquiring an additional 171,609 shares in the last quarter. Marshall Wace LLP lifted its holdings in Esperion Therapeutics by 94.2% in the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after acquiring an additional 2,087,635 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Esperion Therapeutics by 2.7% during the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after purchasing an additional 99,802 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.